Adoptive Cellular Therapy in Acute Myeloid Leukemia: Current Scope and Challenges

Area of Science:

• Hematology
• Immunotherapy
• Oncology

Background:

• Adoptive cellular therapies, like CAR-T cells, have transformed lymphoma and multiple myeloma treatment by targeting specific antigens.
• These therapies face challenges in acute myeloid leukemia (AML) due to shared antigens between AML cells and healthy hematopoietic stem cells (HSCs).

Purpose of the Study:

• This review discusses strategies to overcome the challenges of applying adoptive cellular therapies in AML.
• It focuses on chimeric antigen receptor-T cells (CAR-T) and chimeric antigen receptor-natural killer cells (CAR-NK) for AML treatment.

Main Methods:

• Review of current strategies for developing AML-specific adoptive cellular therapies.
• Discussion of ongoing clinical trials involving CAR-T and CAR-NK cells in AML patients.

Main Results:

• Current adoptive cellular therapies are effective for lymphoma and multiple myeloma but not yet for AML.
• Targeting shared antigens leads to severe myeloablative effects and pancytopenia in AML.

Conclusions:

• Identifying AML-specific antigens is crucial for effective therapy.
• Strategies include limiting CAR-T cell persistence and manipulating HSCs to enable safe adoptive cellular therapies for AML.